US-based Agilent Technologies has introduced its new comparative genomic hybridisation (CGH) assay for use in diagnostic purposes.

Named GenetiSure Dx Postnatal assay, the new device will help clinical geneticists to detect genetic anomalies earlier and more accurately than traditional methods.

The assay is also designed to detect various anomalies, which are related to the developmental delay, intellectual disability, autism, congenital irregularities and dysmorphic features in children and adults.

"From DNA to data analysis, this assay allows for easy implementation into the clinical routine."

Incorporating CGH technology into diagnostics, the GenetiSure Dx Postnatal assay has been developed on the basis of Agilent's collection for comparative genomic hybridisation.

It will also provide data on copy number variations and in absence of heterozygosity, and will carry CE marking for in vitro diagnostics.

In addition, the assay will help identify genetic diagnosis, enabling faster investigation and offering appropriate medical care.

Agilent Technologies genomics solutions division and clinical applications division vice-president and general manager Herman Verrelst said: “The GenetiSure Dx Postnatal Assay has been developed for cytogenetic laboratories, combining high-quality data with easy laboratory setup and streamlined protocols.

“From DNA to data analysis, this assay allows for easy implementation into the clinical routine.”

In October last year, the company launched SureGuide CRISPR libraries for use in functional genomics.

SureGuide features Agilent's oligonucleotide synthesis platform to create clustered regularly interspaced short palindromic repeats (CRISPR) guide libraries, which are a critical component of the CRISPR / Cas genome editing system.